文献

J-GLOBAL ID：201702298698258157   整理番号：17A1165399

前向きコホート研究における膵臓癌リスクのバイオマーカーとしての血漿マイクロRNA【Powered by NICT】

Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study

著者 (66件)： Duell Eric J. (Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain) ,  Lujan-Barroso Leila (Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain) ,  Sala Nuria (Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain) ,  Deitz McElyea Samantha (Department of Medicine, Indiana University School of Medicine, Indianapolis, IN) ,  Overvad Kim (Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus C, Denmark) ,  Tjonneland Anne (Danish Cancer Society Research Center, Copenhagen, Denmark) ,  Olsen Anja (Danish Cancer Society Research Center, Copenhagen, Denmark) ,  Weiderpass Elisabete (Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway) ,  Weiderpass Elisabete (Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden) ,  Weiderpass Elisabete (Department of Community Medicine, University of Tromso, The Arctic University of Norway, Tromso, Norway) ,  Weiderpass Elisabete (Genetic Epidemiology Group, Folkhaelsan Research Center, Helsinki, Finland) ,  Busund Lill-Tove (Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway) ,  Busund Lill-Tove (Department of Medical Biology, UiT The Arctic University of Norway, Tromso, Norway) ,  Moi Line (Department of Clinical Pathology, University Hospital of North Norway, Tromso, Norway) ,  Moi Line (Department of Medical Biology, UiT The Arctic University of Norway, Tromso, Norway) ,  Muller David (School of Public Health, Epidemiology & Biostatistics, Imperial College London, London, United Kingdom) ,  Vineis Paolo (School of Public Health, Epidemiology & Biostatistics, Imperial College London, London, United Kingdom) ,  Aune Dagfinn (School of Public Health, Epidemiology & Biostatistics, Imperial College London, London, United Kingdom) ,  Matullo Giuseppe (Human Genetics Foundation (HuGeF), Turin, Italy) ,  Matullo Giuseppe (Department of Medical Sciences, University of Turin, Turin, Italy) ,  Naccarati Alessio (Human Genetics Foundation (HuGeF), Turin, Italy) ,  Panico Salvatore (Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy) ,  Tagliabue Giovanna (Lombardy Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy) ,  Tumino Rosario (Cancer Registry and Histopathology Unit, “Civic - M.P, Arezzo” Hospital, ASP, Ragusa, Italy) ,  Palli Domenico (Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute-ISPO, Florence, Italy) ,  Kaaks Rudolf (Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Katzke Verena A. (Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany) ,  Boeing Heiner (Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany) ,  Bueno-de-Mesquita H. B(as) (Dt. for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands) ,  Bueno-de-Mesquita H. B(as) (Dt. of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom) ,  Bueno-de-Mesquita H. B(as) (Dt. of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia) ,  Peeters Petra H. (Dept of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands) ,  Peeters Petra H. (MRC-PHE Centre for Environment and Health, Dept of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, United Kingdom) ,  Trichopoulou Antonia (Hellenic Health Foundation, Athens, Greece) ,  Trichopoulou Antonia (WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece) ,  Lagiou Pagona (Hellenic Health Foundation, Athens, Greece) ,  Lagiou Pagona (WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece) ,  Lagiou Pagona (Department of Epidemiology, Harvard School of Public Health, Boston, MA) ,  Kotanidou Anastasia (Hellenic Health Foundation, Athens, Greece) ,  Kotanidou Anastasia (Department of Critical Care Medicine & Pulmonary Services, University of Athens Medical School, Evangelismos Hospital, Athens, Greece) ,  Travis Ruth C. (Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom) ,  Wareham Nick (MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom) ,  Khaw Kay-Tee (MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom) ,  Ramon Quiros Jose (Public Health Directorate, Asturias, Spain) ,  Rodriguez-Barranco Miguel (Andalusian School of Public Health, Research Insititute Biosanitary Granada, University Hospital Granada/University of Granada, Granada) ,  Rodriguez-Barranco Miguel (CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain) ,  Dorronsoro Miren (CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain) ,  Dorronsoro Miren (Basque Regional Health Department, San Sebatian, Spain) ,  Chirlaque Maria-Dolores (CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain) ,  Chirlaque Maria-Dolores (Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain) ,  Ardanaz Eva (CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain) ,  Ardanaz Eva (Navarra Public Health Institute, Pamplona, Spain) ,  Ardanaz Eva (IdiSNA, Navarra Institute for Health Research, Pamplona, Spain) ,  Severi Gianluca (Universite Paris-Saclay, Universite Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France) ,  Severi Gianluca (Gustave Roussy, Villejuif, France) ,  Boutron-Ruault Marie-Christine (Universite Paris-Saclay, Universite Paris-Sud, UVSQ, CESP, INSERM, Villejuif, France) ,  Boutron-Ruault Marie-Christine (Gustave Roussy, Villejuif, France) ,  Rebours Vinciane (Beaujon Hospital, Pancreatology Unit, Clichy, France) ,  Rebours Vinciane (INSERM, University Paris, France) ,  Brennan Paul (International Agency for Research on Cancer (IARC), Lyon, France) ,  Gunter Marc (International Agency for Research on Cancer (IARC), Lyon, France) ,  Scelo Ghislaine (International Agency for Research on Cancer (IARC), Lyon, France) ,  Cote Greg (Medical University of South Carolina, Charleston, SC) ,  Sherman Stuart (Department of Medicine, Indiana University School of Medicine, Indianapolis, IN) ,  Korc Murray (Departments of Medicine and Biochemistry & Molecular Biology, Indiana University School of Medicine, Indianapolis, IN) ,  Korc Murray (Pancreatic Cancer Signature Center, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN)
資料名： International Journal of Cancer  (International Journal of Cancer)
巻： 141  号： 5  ページ： 905-915  発行年： 2017年 
JST資料番号： A0267B  ISSN： 0020-7136  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 初期膵管腺癌(PDAC)診断と疾患リスク層別化のための非侵襲的バイオマーカーの必要性が高まっている。PDACリスクのバイオマーカーとしての診断前のマイクロRNA(miR)を評価するためにinto Cancer and Nutrition(EPIC)コホート前向き調査に組み込まれた症例対照研究を実施した。著者らのグループによる以前の証拠に基づく八miR(miR-10a, 10b, 21から 3p, 21から 5p, 30C, 106b, 155および 212)のパネルは225微視的に確認したPDAC例,225制御センター,性別,絶食状態と年齢/日/時間採血の整合で評価した。診断前の血漿試料中のMiRレベルを定量的RT-PCRにより決定した。ロジスティック回帰はレベルとPDACリスクをモデル化し,共変量を調整し,受信者動作特性曲線下面積(AUC)を推定した。プラズマmiR 10b, 21 5P, 30Cおよび 106bの量は2年マッチした対照(全てのp値<0.04)と比較して採血の以内に診断された症例で有意に高かった。調整ロジスティック回帰モデルに基づいて,採血と診断(≦5 yr,≦2 yr)間のより短い経過観察時四miR( 10a, 10b, 21から 5pと 30C),六全体miR(miR-10a, 10b, 21から 5p, 30C, 155および 212)のレベルはリスクと統計的に有意であった。パネルに基づくスコアは,リスク(p値=0.0006)と線形用量反応傾向を示した。より短い追跡(≦5 yr)では,スコアのAUCは0.73であり,個々のmiRの0.73(miR 212)から0.79の範囲にあった(miR 21 5p)。Copyright 2017 Wiley Publishing Japan K.K. All Rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： 症例対照研究 ,  *血漿 ,  採血 ,  *前向きコホート研究 ,  パネル ,  RT-PCR法 ,  *膵臓腫瘍 ,  血中濃度-時間曲線下面積 ,  *母集団 ,  *バイオマーカー ,  モデリング
準シソーラス用語： スコア ,  p値 ,  ロジスティック回帰分析 ,  *マイクロRNA , 【Automatic Indexing@JST】

著者キーワード (4件)： バイオマーカー ,  マイクロRNA ,  すい癌 ,  コホート研究

分類 (2件)： 臨床腫よう学一般  (GE03010Y) ,  疫学  (GB03000E)

タイトルに関連する用語 (6件)： 前向きコホート研究 ,  膵臓癌 ,  リスク ,  バイオマーカー ,  血漿 ,  マイクロRNA